VanEck announced today its distributions per share for its VanEck Vectors® exchange-traded funds. The following dates apply to distribution declarations for the funds listed below:...
VanEck announced today its regular distribution per share for the following VanEck Vectors® equity exchange-traded fund. ...
ESPO provides targeted exposure to “the future of sports”: video game and related software developers, streaming services, companies involved in eSports events, and more VanEck today...
VanEck announced today its regular distributions per share for the VanEck Vectors® equity exchange-traded funds. Ex-Date...
VanEck announced today its regular distributions per share for its VanEck Vectors® equity exchange-traded funds. Ex-Date Record Date ...
VanEck announced today its regular distributions per share for its VanEck Vectors® equity exchange-traded funds. Ex-Date Record Date ...
- Treatment in Combination with Radiation Doubled Survival Time and Produced Long-Term Cures in Lethal Brain Cancer Model - - Confirms PS-Targeting Antibodies Have a Dual Mechanism of Action that...
--Broad New Patent Covers Peregrine's Lead PS-Targeting Antibody Bavituximab and Similar Agents for the Treatment of All Viral Infections-- --New Patent Covers Applications under Active...
TUSTIN, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHMD) today announced that on November 3, 2009, the Company received notice from the NASDAQ Market...
- 28 of 46 (61%) Patients Receiving Bavituximab in Combination with Docetaxel Achieved Objective Tumor Response by End of Planned Treatment Cycles - - Tumor Response Data Compares Favorably with...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約